comparemela.com
  1. Home
  2. Live Updates
  3. Molecular Templates - Breaking News

Latest Breaking News On - Molecular templates - Page 1 : comparemela.com

CTLA-4 Inhibitors Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism Of Action, Route Of Administration, And Comp



United statesInnovent biologicsBristol myers squibbAkeso biopharmaDrugs under different phases of clinical developmentPharmaceuticals incDrug administrationUniversity collaborations licensing partnering analysisAlpine immune sciencesAkeso biopharma co ltdRoute of administrationBiocytogen pharmaceuticalsInhibitors companiesMolecular templates incAkeso incKey companies

Molecular Templates, Inc (NASDAQ:MTEM) Short Interest Down 21 9% in May

Molecular Templates, Inc. (NASDAQ:MTEM – Get Free Report) saw a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 132,100 shares, a drop of 21.9% from the April 30th total of 169,100 shares. Based on an average daily volume of 75,500 shares, the short-interest ratio […]

United statesSecurities exchange commissionMolecular templates incSilverarc capital managementMolecular templatesGet free reportCapital managementFree reportMolecular templates daily

Molecular Templates, Inc (NASDAQ:MTEM) Shares Sold by Monashee Investment Management LLC

Molecular Templates, Inc (NASDAQ:MTEM) Shares Sold by Monashee Investment Management LLC
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United statesSilverarc capital managementMonashee investment managementMolecular templates incMolecular templates company profileExchange commissionMolecular templatesFree reportInvestment managementTemplates trading downGet free reportMolecular templates daily

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiSouth koreaJin wangGenentechf hoffmannAsher biotherapeuticsDaiichi sankyoChipscreen biosciencesBristol myers squibbAshfield medcommsMerck biopharmMerck seronoSamsung bioepisLyell immunopharmaCalithera biosciencesEli lilly

MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024

MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Market newsStock adviceMolecular templatesMolecular templates beatsBeats revenue
© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.